What’s New in Systemic Lupus Erythematosus?
Unlocking Novel Paths to Patient Care
Meeting Slides
Classification Criteria
2019 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus.
Aringer M, et al. Arthritis Rheumatol. 2019;71(9):1400-1412.
Disease Management Guidelines
2019 update of the EULAR recommendations for the management of systemic lupus erythematosus.
Fanouriakis A, et al. Ann Rheum Dis. 2019;78(6):736-745.
Patient Resources
American College of Rheumatology
Lupus Foundation of America
Lupus Research Alliance
Disease Activity Indices
Use of Physician Global Assessment in systemic lupus erythematosus: a systematic review of its psychometric properties.
Chessa E, et al. Rheumatology (Oxford). 2020 doi 10.1093/rheumatology/keaa383
Lupus low disease activity state as a treatment endpoint for systemic lupus erythematosus: a prospective validation study.
Golder V, et al. Lancet Rheumatol. 2019;1(2):e95-e102.
BILAG 2004. Development and initial validation of an updated version of the British Isles Lupus Assessment Group’s disease activity index for patients with systemic lupus erythematosus.
Isenberg DA, et al. Rheumatology (Oxford). 2005;44(7):902-906.
Development and initial validation of the Systemic Lupus Erythematosus Disease Activity Index 2000 Responder Index 50.
Touma Z, et al. J Rheumatol. 2011;38(2):275-284.
Suggested Readings
European League Against Rheumatism (EULAR) 2020 Annual Meeting Abstracts.
June 3-6, 2020. Virtual.
American College of Rheumatology (ACR) Annual Meeting Abstracts.
November 5-9, 2020. Virtual.
Treat-to-target in systemic lupus erythematosus: recommendations from an international task force.
van Vollenhoven RF, et al. Ann Rheum Dis. 2014;73(6):958-967.
Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1): a randomised, controlled, phase 3 trial.
Furie RA, et al. Lancet Rheumatol. 2019;1(4):e208-e219.
Trial of anifrolumab in active systemic lupus erythematosus.
Morand EF, et al. N Engl J Med. 2020;382(3):211-221.
Anifrolumab, an anti–interferon-α receptor monoclonal antibody, in moderate-to-severe systemic lupus erythematosus.
Furie R, et al. Arthritis Rheumatol. 2017;69(2):376-386.
A phase 3, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus.
Furie R, et al. Arthritis Rheum. 2011;63(12):3918-3930.
Two-year, randomized, controlled trial of belimumab in lupus nephritis.
Furie RA, et al. N Engl J Med. 2020;383(12):1117-1128.
Lupus Low Disease Activity State (LLDAS) attainment discriminates responders in a systemic lupus erythematosus trial: post-hoc analysis of the Phase IIb MUSE trial of anifrolumab.
Morand EF, et al. Ann Rheum Dis. 2018;77(5):706-713.
Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial.
Navarra SV, et al. Lancet. 2011;377(9767):721-731.
AURORA phase 3 study demonstrates voclosporin statistical superiority over standard of care in lupus nephritis.
Arriens C, et al. Ann Rheum Dis. 2020;79(suppl 1):172-173.
B-cell depletion and response in a randomized, controlled trial of obinutuzumab for proliferative lupus nephritis.
Furie R, et al. Lupus Sci Med. 2020;7(suppl 1):A27-A28.
Comprehensive efficacy of anifrolumab across organ domains in patients with active SLE: pooled data from 2 phase 3 trials.
Morand E, et al. Arthritis Rheumatol. 2020;72(suppl 10).
Flare reduction and oral corticosteroid taper in patients with active SLE treated with anifrolumab in 2 phase 3 trials.
Furie R, et al. Arthritis Rheumatol. 2020;72(suppl 10).
Interactive PresentationImmunopathogenesis of SLE
Additional Q&A From Live Syposium Featuring Dr. Richard Furie
Unlocking Novel Paths to Patient Care
Relevant Resources
Improved Diagnostic and Management Strategies
Balancing the Benefits and Risk of Opioid-Based Therapy
Individualized Assessment and Mechanism-Based Multimodal Treatment
Responsible Opioid Prescribing to Achieve Individualized Functional Goals
Long-Term Management Strategies to Improve Patient Outcomes
Overcoming Pain and Gastrointestinal Distress to Improve Patient Outcomes
Proactive Diagnosis and Targeted Management
Selecting Patients and Optimizing Long-Term Outcomes
Evidence-Based Strategies for Improved Patient Outcomes
Proactive Diagnosis and Targeted Management
Differential Diagnosis and Comprehensive Management Strategies
Optimizing Maintenance Therapy Across Healthcare Settings
Evolving Strategies for Diagnosis and Long-Term Management
Consensus and Controversies for Responsible Opioid Prescribing
Best Practices in Combination Therapy
The Role of Nurses in Optimizing Long-term Outcomes
Evolving Approaches to Insulin Based Therapy
Evolving Best-Practice Strategies to Maximize Efficacy and Safety
Treating to Target, IL-6-Directed Therapies, and Evolving Management Algorithms
Improving Outcomes for Patients with COPD
New Strategies for Insulin Replacement Therapy
Clinical Updates in LDL-C Management
Improving Comprehensive Patient Care
Identifying Patients and Tailoring Therapy
Collaborative Approaches to Guideline-Concordant Patient Care
New Strategies for Individualizing Long-term Care
A Focus on Patients With Opioid-Induced Constipation
Consensus and Controversies Across the Spectrum of Patient Presentations
Evolving Treatment Algorithms and Expert Perspectives on Biosimilars
Patient Selection, Treatment Initiation, and Ongoing Monitoring
Pathophysiology to the Management of Moderate-to-Severe Disease
Engaging With Patients About Opioid-Induced Constipation
Evolving Best Practices to Optimize Outcomes
Targeting Immune Dysregulation and Delivering Comprehensive Care
The PCP’s Role in Timely Recognition and Referral
Translating Comprehensive Patient Evaluations Into Personalized Therapy
Looking Beyond Barriers to Optimize Therapy
New Perspectives on Targeting Remission and Individualizing Therapy
Using Imaging to Improve Patient Outcomes
Debates and Discussions About Therapeutically Targeting Nerve Growth Factor Signaling
Discussions and Debates on the Evolving Roles of Targeted Synthetic DMARDs
Differential Diagnosis, Multidisciplinary Management, and Patient Engagement
Key Issues Impacting OB/GYN Practice
Expanding the Conversation on Opioid-Induced Constipation
Translating Pathophysiology into Targeted Treatments
Think You Know JAK?
An Interactive Experience Highlighting Recent Clinical Advances
Volume II: Expanding Evidence for the Role of Rapid ART Initiation in HIV Practice
Debates & Discussions on the Evolving Role of JAK Inhibitors
Translating Guidelines Into Patient Care
Improving Patient Outcomes Through Shared Clinical Decision Making
Mechanistic Insights and Evolving Treatment Options
Clinical Resource Center
The Evolving Role of JAK Inhibitors
Unpacking the Evidence for Their Use Today and Tomorrow
A Case-Based Conversation on Managing Asthma and Chronic Rhinosinusitis With Nasal Polyposis
The Clinical and Utilization Benefits of Exacerbation Prevention
A PrEP Primer
A Foundation for Managed Care
Cardiovascular and Renal Outcomes With SGLT2 Inhibitors
Best Practices for Primary Care
New Paths to Chronic Pain Management
What the Pharmacist Needs to Know about PrEP
The Increasing Role of JAK Inhibitors
Unlocking Novel Paths to Patient Care
New Pathways to Patient Management
A Focus on Clinical Evidence and Guideline Recommendations
Preventing COPD Exacerbations to Improve Outcomes
A Whole Patient Case Series
New Avenues to the Management of Severe Asthma
Getting on the Fast Track to Identify AxSpA
Establishing Clinical Readiness Through Mentored Learning
Interdisciplinary Strategies for Adult and Pediatric Patients
Interdisciplinary Management of Eosinophilic Esophagitis and Hereditary Angioedema
Reducing LDL-C and a Lifetime of Cardiovascular Risk
Updates, Clinical Scenarios, and Future Directions
A Multidisciplinary Look at Early Diagnosis and Management
Finding the Path in Chronic Rhinosinusitis with Nasal Polyps
Best Practices for Diagnosis and Management
An Update on Best Practices
New Avenues to Pre-Exposure Prophylaxis
Are You Aware of New Blood-Based Multi-Cancer Screening Tools
From Patient Evaluations to New Targeted Therapies
A Look at the Changing HIV Playing Field
A “How To” Series Spanning Policy to Practice
Test Your Mastery!
Building Bridges to Reach People who Inject Drugs with the Goal of Employing PrEP for HIV Prevention
Strengthening Your Knowledge of Blood-Based Screening Tools
Bringing HIV Prevention to a New Level
Optimizing HIV Prevention in Primary Care
